Special Issue

Multi-Drug Resistant Gram-Negative Infections: Molecular Epidemiology, Microbiological Diagnosis and Antimicrobial Treatment

Message from the Guest Editors

Infections caused by gram-negative pathogens have become increasingly prevalent in recent years, representing a serious global threat to public health. The majority of the burden is related to healthcare-acquired infections caused by gram-negative multi-drug resistant organisms, including extended-spectrum β-lactamase (ESBL-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant *Acinetobacter baumannii* (CRAB), and MDR *Pseudomonas aeruginosa*. We invite authors to send in their manuscripts in the following areas of interest:

- novel in vitro diagnostic tools for MDR gram-negative detection and antimicrobial susceptibility testing;
- molecular epidemiology of gram-negative pathogens and resistance mechanisms;
- evaluation of antimicrobial treatment regimens for MDR gram-negatives infections;
- new drugs against MDR gram-negatives: clinical use, in vitro susceptibility testing and emerging resistance.

Guest Editors

Dr. Simone Ambretti

Dr. Paolo Gaibani

Dr. Tommaso Giani

Deadline for manuscript submissions

closed (31 December 2022)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/87048

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI